Peter M Schmidt

List of Publications by Citations

34 papers	2,418 citations	22 h-index	35 g-index
35 ext. papers	2,597 ext. citations	6.9 avg, IF	4.12 L-index

#	Paper	IF	Citations
34	NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. *Nature Reviews Drug Discovery*, **2006**, 5, 755-68	64.1	528
33	The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells. *Neuron*, **2006**, 49, 67-79	13.9	345
32	Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. *Journal of Clinical Investigation*, **2006**, 116, 2552-61	15.9	344
31	NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. *British Journal of Pharmacology*, **2002**, 136, 773-83	8.6	234
30	Identification of residues crucially involved in the binding of the heme moiety of soluble guanylate cyclase. *Journal of Biological Chemistry*, **2004**, 279, 3025-32	5.4	135
29	NO- and haem-independent soluble guanylate cyclase activators. *Handbook of Experimental Pharmacology*, **2009**, 309-39	3.2	108
28	Nitric oxide-independent vasodilator rescues heme-oxidized soluble guanylate cyclase from proteasomal degradation. *Circulation Research*, **2009**, 105, 33-41	15.7	91
27	Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. *European Journal of Pharmacology*, **2003**, 468, 167-74	5.3	76
26	Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. *British Journal of Pharmacology*, **2009**, 157, 781-95	8.6	53
25	NO-independent regulatory site of direct sGC stimulators like YC-1 and BAY 41-2272. *BMC Pharmacology*, **2001**, 1, 13		51
24	Dimerization region of soluble guanylate cyclase characterized by bimolecular fluorescence complementation in vivo. *Molecular Pharmacology*, **2007**, 72, 1181-90	4.3	43
23	Identification and localization of connexin26 within the photoreceptor-horizontal cell synaptic complex. *Visual Neuroscience*, **2001**, 18, 169-78	1.7	41
22	Microgravity-induced alterations in signal transduction in cells of the immune system. *Acta Astronautica*, **2010**, 67, 1116-1125	2.9	38
21	A generic system for the expression and purification of soluble and stable influenza neuraminidase. *PLoS ONE*, **2011**, 6, e16284	3.7	36
20	Residues stabilizing the heme moiety of the nitric oxide sensor soluble guanylate cyclase. *European Journal of Pharmacology*, **2005**, 513, 67-74	5.3	33
19	Real time enzyme inhibition assays provide insights into differences in binding of neuraminidase inhibitors to wild type and mutant influenza viruses. *PLoS ONE*, **2011**, 6, e23627	3.7	32
18	The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rat platelets. *Journal of Cardiovascular Pharmacology*, **2000**, 35, 390-7	3.1	32

List of Publications

17	Identification of residues crucially involved in soluble guanylate cyclase activation. *FEBS Letters*, **2006**, 580, 4205-13	3.8	29
16	Fluorescence dequenching makes haem-free soluble guanylate cyclase detectable in living cells. *PLoS ONE*, **2011**, 6, e23596	3.7	25
15	rIgG1 Fc Hexamer Inhibits Antibody-Mediated Autoimmune Disease via Effects on Complement and FcRs. *Journal of Immunology*, **2018**, 200, 2542-2553	5.3	24
14	Targeting coagulation factor XII as a novel therapeutic option in brain trauma. *Annals of Neurology*, **2016**, 79, 970-82	9.4	24
13	A robust robotic high-throughput antibody purification platform. *Journal of Chromatography A*, **2016**, 1455, 9-19	4.5	22
12	Taking down the FLAG! How insect cell expression challenges an established tag-system. *PLoS ONE*, **2012**, 7, e37779	3.7	18
11	Preparation of heme-free soluble guanylate cyclase. *Protein Expression and Purification*, **2003**, 31, 42-6	2	15
10	Biochemical Detection of cGMP From Past to Present: An Overview. *Handbook of Experimental Pharmacology*, **2009**, 195-228	3.2	10
9	Phenotype-specific recombinant haptoglobin polymers co-expressed with C1r-like protein as optimized hemoglobin-binding therapeutics. *BMC Biotechnology*, **2018**, 18, 15	3.5	9
8	Receptor binding assay for nitric oxide- and heme-independent activators of soluble guanylate cyclase. *Analytical Biochemistry*, **2003**, 314, 162-5	3.1	7
7	Structure of an Influenza A virus N9 neuraminidase with a tetrabrachion-domain stalk. *Acta Crystallographica Section F, Structural Biology Communications*, **2019**, 75, 89-97	1.1	4
6	Optimizing high throughput antibody purification by using continuous chromatography media. *Protein Expression and Purification*, **2019**, 159, 75-82	2	4
5	FVIII half-life extension by coadministration of a DTD3 albumin fusion protein in mice, rabbits, rats, and monkeys. *Blood Advances*, **2020**, 4, 1870-1880	7.8	3
4	Receptor binding assay for NO-independent activators of soluble guanylate cyclase. *Methods in Molecular Biology*, **2013**, 1020, 205-14	1.4	2
3	Beyond NO and heme: biochemical and pharmacological opportunities. *BMC Pharmacology*, **2005**, 5, S18		2
2	Technical Optimization for the High-Throughput Purification of Antibodies on Automated Liquid Handlers. *Methods in Molecular Biology*, **2021**, 2178, 49-62	1.4	0
1	Formation of quasi-covalent sGC 1/1-heterodimers by ODQ-induced oxidation of the prosthetic heme moiety. *BMC Pharmacology*, **2005**, 5, P40		